Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy

Status Completed

Clinical Trial Summary

The neurological alterations associated with preeclampsia depend on cerebral autoregulation, a theory that outlines the mechanisms by which the nervous system controls cerebral perfusion. However, with the loss of autoregulation, increased blood flow, edema and eventually increased intracranial pressure are triggered and may be translated into neurological manifestations such as symptoms of vasospasm, one of the criteria for severity in preeclampsia. Nervous system manifestations frequently found in preeclampsia are headache, blurred vision, scotomas and hyperreflexia. Although uncommon, temporary blindness (lasting a few hours to a week) may also accompany severe preeclampsia and eclampsia. The optic nerve, as part of the central nervous system, is surrounded by cerebrospinal fluid and dura mater, which forms the optic nerve sheath. Due to the connection with the intracranial subarachnoid space, the diameter of the optic nerve sheath is influenced by variations in cerebrospinal fluid pressure. Increased intracranial pressure is transmitted to the subarachnoid space surrounding the optic nerve, causing its expansion. Recent studies suggest that an optic nerve sheath diameter greater than 5 mm correlates 100% with ICP (intracerebral pressure) greater than 20 mm Hg. Due to the simple nature of the test and the limited time required to perform it, it is an ideal non-invasive test to assess changes in mental status, severe headache, and to take the necessary measures aimed at reducing intracranial pressure. The diagnosis of elevated intracranial pressure is challenging and critical, because early recognition and treatment are essential to prevent brain damage or death since preeclampsia with severe data remains one of the most frequent complications in our institution. These values are not taken from the obstetric population, so this study proposes the description of a standard value for the pregnant population. There are few studies that describe a value to help us define cases of this pathology and correlate it with the signs and symptoms of severity in patients with preeclampsia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05594056
Study type	Interventional
Source	Saint Thomas Hospital, Panama
Contact
Status	Completed
Phase	N/A
Start date	October 21, 2022
Completion date	January 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04243278` - Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)	Early Phase 1
Not yet recruiting	`NCT03318211` - Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial	Phase 4
Recruiting	`NCT03761888` - Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
Not yet recruiting	`NCT06373367` - Preeclampsia Educational Program Study (PrEPS)	N/A
Not yet recruiting	`NCT04855513` - Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial	N/A
Not yet recruiting	`NCT05232994` - Metformin and Esomeprazole For Preterm Pre-eclampsia	Phase 1
Completed	`NCT04392375` - Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor	Phase 4
Recruiting	`NCT03978767` - Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial	Phase 2
Completed	`NCT04236258` - Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period	Phase 4
Completed	`NCT04756661` - Uterotonics for Severe Preeclampsia	N/A
Active, not recruiting	`NCT04660032` - Nudge to Drive Transitions of Care	N/A
Completed	`NCT04103489` - The Use of Eculizumab in HELLP Syndrome	Phase 1
Enrolling by invitation	`NCT04794855` - Risk Prediction Model of Preeclampsia
Recruiting	`NCT04311749` - Expanded NIPT for Pregnancy Complications
Active, not recruiting	`NCT06359015` - Metformin and Esomeprazole in Preterm Pre-eclampsia	Phase 4
Recruiting	`NCT05610774` - Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine	N/A
Completed	`NCT03815110` - Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
Completed	`NCT03210350` - Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients
Completed	`NCT03451266` - Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia	Phase 1
Active, not recruiting	`NCT06360601` - Intravenous Labetalol Versus Hydralazine in Preeclampsia	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy Pregnant Women and Those With Severe Preeclampsia.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms